1. Home
  2. KRNT vs OMER Comparison

KRNT vs OMER Comparison

Compare KRNT & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kornit Digital Ltd.

KRNT

Kornit Digital Ltd.

HOLD

Current Price

$16.03

Market Cap

668.4M

Sector

Industrials

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$13.42

Market Cap

772.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRNT
OMER
Founded
2002
1994
Country
Israel
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
668.4M
772.8M
IPO Year
2014
2008

Fundamental Metrics

Financial Performance
Metric
KRNT
OMER
Price
$16.03
$13.42
Analyst Decision
Buy
Strong Buy
Analyst Count
4
5
Target Price
$19.75
$32.50
AVG Volume (30 Days)
299.3K
1.2M
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
98.15
EPS
N/A
N/A
Revenue
N/A
$29,868,000.00
Revenue This Year
$4.52
N/A
Revenue Next Year
$7.84
$233.22
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.93
$2.95
52 Week High
$23.48
$17.65

Technical Indicators

Market Signals
Indicator
KRNT
OMER
Relative Strength Index (RSI) 57.54 65.64
Support Level $14.13 $10.82
Resistance Level $16.33 $17.65
Average True Range (ATR) 0.51 0.62
MACD -0.01 0.21
Stochastic Oscillator 65.71 85.27

Price Performance

Historical Comparison
KRNT
OMER

About KRNT Kornit Digital Ltd.

Kornit Digital Ltd develops, designs and markets digital printing solutions for the world-wide printed textile industry. The company focuses on its DTG and DTF segments of the printed textile industry. Its solutions include digital printing systems, ink and other consumables, associated software and value-added services that allow for large-scale printing of short runs of complex images and designs directly on finished garments and fabrics. It generates revenue from sales of systems, ink and other consumables and service including software subscriptions The company geographically operates in U.S., EMEA, Asia Pacific and other countries. It derives maximum revenue from U.S.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: